Trial Profile
A Dose Blocked-randomized, Double-blind, Placebo Controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamics and Food Effect of LC51-0255
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2020
Price :
$35
*
At a glance
- Drugs Zectivimod (Primary)
- Indications Autoimmune disorders; Inflammation; Ulcerative colitis
- Focus Adverse reactions
- Sponsors LG Chem
- 16 Sep 2020 Status changed from recruiting to completed.
- 19 May 2020 Results (n=50)evaluating the safety, tolerability and pharmacokinetic (PK)/ pharmacodynamic (PD) characteristics of multiple ascending doses of LC51-0255 as a potential treatment of auto-immune diseases such as ulcerative colitis published in Gasteroenterology in conjunction with Digestive Disease Week 2020
- 14 May 2020 Results published in the LG Chem Media Release.